drugset / Trial / NCT00763438

Safety Study of an Antipsychotic, Sertindole, to Treat Schizophrenia

NCT00763438

Phase 4 Completed 18 enrolled H. Lundbeck A/S
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to permit the patients with schizophrenia who received Sertindole during a previous randomised trial, study 99824, to continue with this treatment.

Timeline

Start
2007-11
Primary completion
2010-07
Completion
2010-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Sertindole Small molecule

Indications